Glycomics Research Projects

Our core’s research strength is glycomics research, and we have tried to provide consulting and supportive activities to Emory research community, but this area is still growing only slowly at Emory.  The bulk of our use is coming from the three glycomics labs left at Emory; Sean Stowell, Xuscheng Song, and Dave Smith.  We use the core extensively, and most of our revenue is probably generated from our grant support.  We are generating some interest from other labs on campus; including David Steinhauer and Dick Compans in Microbiology; Max Cooper in the Vaccine Center, and Bill Dynan in Radiation Oncology. 

We have written letters to support grant applications for the following investigators:

Dr. Xuezheng Song, Biochemistry

Sean Stowell, Pathology

David Steinhauer, Microbiology

Dick Compans, Microbiology

Max Cooper, Vaccine Center

Bill Dynan, Radiation Oncology

We have written letters to support grant applications for the following investigators outside of Emory:

Rene Ranzinger, CRC, University of Georgia, Athens, GA

Dr. Jian Zhang, Z-Biotech, Aurora, CO

Dr. B.V.Venkataram Prasad, Baylor College of Medicine, Houston, TX

Dr. Raed Dweik, Lerner Research Institute, Department of Pathobiology,Cleveland, OH

Dr. John Cipollo, US FDA, Rockville, MD

Brian Haab, Van Andel Institute, Grand Rapids, MI

Dr. Thierry Hennet, Institute of Physiology, University of Zurich, Switzerland


We had hoped that the availability of Glycomics and glycoscience on the Emory Campus would be growing a bit faster.  We generally have good turn outs for the Glycomic Data Club meetings, but because there are not more investigators doing glycomics, we have less opportunity for internal speakers. Of course loosing faculty, who are interested in glycomics is not helpful, and we appreciate the effort the Dean made in trying to retain Dr. Tongzhong Ju, who moved to the FDA in Bethesda.  Recruiting new faculty that use or require glycoscience would also be helpful.  There are many areas that now are discovering the need for glycoscience. For example Andrew Adams, MD, PhD, Division of Transplantation, Emory SOM is working on Xenotransplantation using pig organs that focuses on glycan antigens that cause organ rejection.

In this regard, we could probably strengthen the glycomics program by becoming a bit more comprehensive by providing a broader set of services; i.e., adding more glycosciences services.  That would require, however, adding additional trained staff and instrumentation.  Another approach might be to bring a closer relationship between the glycomic, proteomics, and lipidomics Cores where there can be large potential overlaps and technology sharing.